NR 565 Midterm Exam Advanced Pharmacology Fundamentals
Chamberlain College of Nursing Question Bank (Latest 2026/2027
Edition) – 100% Correct Questions, Answers & Detailed Rationales
Total Questions: 50
Time Allowed: 90 Minutes
Passing Score: 80%
Instructions: Select the BEST answer for each question based on advanced
pharmacology principles, pharmacokinetics, pharmacodynamics, and evidence-based
prescribing. For SATA questions, select all that apply.
SECTION 1: PHARMACOKINETICS (ADME)
Questions 1–11
1. A 45-year-old patient with a history of GERD is prescribed omeprazole, which is a
prodrug activated by hepatic CYP2C19 enzymes. The APRN is counseling the patient on
why prodrugs are used in clinical practice. Which statement best explains the clinical
rationale for using prodrugs?
A. Prodrugs are always less expensive than their active metabolites.
B. Prodrugs are pharmacologically inactive until metabolized, which can improve
absorption, reduce toxicity, or enhance delivery to target tissues.
,C. Prodrugs bypass the first-pass effect entirely, resulting in 100% bioavailability.
D. Prodrugs are primarily used to increase renal excretion of active drugs.
Correct Answer: B
Rationale: Prodrugs are pharmacologically inactive compounds that are converted to
active forms through metabolic processes. This design can enhance lipid solubility for
improved absorption (e.g., crossing the blood-brain barrier), reduce gastrointestinal
toxicity by limiting direct drug exposure, or improve targeting to specific tissues.
Omeprazole is a classic example: it is activated in the acidic environment of parietal cell
canals, not systemically by CYP2C19 (though CYP2C19 metabolizes it). Prodrugs do not
guarantee 100% bioavailability (first-pass effect still applies), nor are they primarily used
to increase renal excretion or reduce cost.
2. A patient is prescribed a newly formulated extended-release tablet of a drug that is
also available as an immediate-release tablet. The APRN explains that the
extended-release formulation has a lower bioavailability than the immediate-release
formulation. Which concept best explains this clinical observation?
A. Chemical equivalence
B. Bioavailability equivalence
C. Therapeutic index
D. First-pass metabolism
Correct Answer: B
Rationale: Bioavailability refers to the rate and extent of drug absorption into systemic
circulation. Two formulations of the same drug may be chemically equivalent (same
,active ingredient) but not bioequivalent (different absorption rates/extents).
Extended-release formulations often have lower peak concentrations and sometimes
lower overall bioavailability compared to immediate-release forms due to slower
dissolution and absorption. The first-pass effect affects all oral formulations equally for
the same drug. Therapeutic index relates to safety margin, not formulation differences.
3. A 68-year-old patient with chronic kidney disease (eGFR 35 mL/min) is prescribed a
renally excreted antibiotic. The APRN must adjust the dose. Which pharmacokinetic
phase is most directly affected by this patient's renal impairment?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Correct Answer: D
Rationale: Excretion is the elimination of drugs from the body, primarily via renal
(kidney) and hepatic (biliary) routes. In chronic kidney disease with reduced eGFR, the
kidneys' ability to filter and excrete drugs and their metabolites is significantly impaired.
This leads to drug accumulation and increased risk of toxicity. While renal impairment
can secondarily affect some drug distributions (e.g., protein binding changes due to
uremia), the primary pharmacokinetic concern is reduced excretion. Absorption and
hepatic metabolism are less directly affected by renal impairment.
, 4. A patient asks the APRN why some medications are given intravenously rather than
orally. The APRN explains that the intravenous route bypasses which pharmacokinetic
process that significantly reduces bioavailability for many oral drugs?
A. Distribution
B. Protein binding
C. First-pass effect
D. Renal clearance
Correct Answer: C
Rationale: The first-pass effect (first-pass metabolism) occurs when a drug absorbed
from the gastrointestinal tract travels via the portal vein to the liver before entering
systemic circulation. In the liver, CYP450 enzymes metabolize a significant portion of
the drug, reducing its bioavailability. Intravenous administration delivers drugs directly
into systemic circulation, completely bypassing the first-pass effect and achieving 100%
bioavailability (by definition). Distribution, protein binding, and renal clearance occur
after the drug enters circulation regardless of route.
5. A 55-year-old patient is started on warfarin 5 mg daily. The APRN explains that it will
take approximately 5–7 days to achieve a therapeutic INR. Which pharmacokinetic
concept best explains this delayed therapeutic effect?
A. Zero-order kinetics
B. Steady-state concentration
C. Loading dose requirement
Chamberlain College of Nursing Question Bank (Latest 2026/2027
Edition) – 100% Correct Questions, Answers & Detailed Rationales
Total Questions: 50
Time Allowed: 90 Minutes
Passing Score: 80%
Instructions: Select the BEST answer for each question based on advanced
pharmacology principles, pharmacokinetics, pharmacodynamics, and evidence-based
prescribing. For SATA questions, select all that apply.
SECTION 1: PHARMACOKINETICS (ADME)
Questions 1–11
1. A 45-year-old patient with a history of GERD is prescribed omeprazole, which is a
prodrug activated by hepatic CYP2C19 enzymes. The APRN is counseling the patient on
why prodrugs are used in clinical practice. Which statement best explains the clinical
rationale for using prodrugs?
A. Prodrugs are always less expensive than their active metabolites.
B. Prodrugs are pharmacologically inactive until metabolized, which can improve
absorption, reduce toxicity, or enhance delivery to target tissues.
,C. Prodrugs bypass the first-pass effect entirely, resulting in 100% bioavailability.
D. Prodrugs are primarily used to increase renal excretion of active drugs.
Correct Answer: B
Rationale: Prodrugs are pharmacologically inactive compounds that are converted to
active forms through metabolic processes. This design can enhance lipid solubility for
improved absorption (e.g., crossing the blood-brain barrier), reduce gastrointestinal
toxicity by limiting direct drug exposure, or improve targeting to specific tissues.
Omeprazole is a classic example: it is activated in the acidic environment of parietal cell
canals, not systemically by CYP2C19 (though CYP2C19 metabolizes it). Prodrugs do not
guarantee 100% bioavailability (first-pass effect still applies), nor are they primarily used
to increase renal excretion or reduce cost.
2. A patient is prescribed a newly formulated extended-release tablet of a drug that is
also available as an immediate-release tablet. The APRN explains that the
extended-release formulation has a lower bioavailability than the immediate-release
formulation. Which concept best explains this clinical observation?
A. Chemical equivalence
B. Bioavailability equivalence
C. Therapeutic index
D. First-pass metabolism
Correct Answer: B
Rationale: Bioavailability refers to the rate and extent of drug absorption into systemic
circulation. Two formulations of the same drug may be chemically equivalent (same
,active ingredient) but not bioequivalent (different absorption rates/extents).
Extended-release formulations often have lower peak concentrations and sometimes
lower overall bioavailability compared to immediate-release forms due to slower
dissolution and absorption. The first-pass effect affects all oral formulations equally for
the same drug. Therapeutic index relates to safety margin, not formulation differences.
3. A 68-year-old patient with chronic kidney disease (eGFR 35 mL/min) is prescribed a
renally excreted antibiotic. The APRN must adjust the dose. Which pharmacokinetic
phase is most directly affected by this patient's renal impairment?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Correct Answer: D
Rationale: Excretion is the elimination of drugs from the body, primarily via renal
(kidney) and hepatic (biliary) routes. In chronic kidney disease with reduced eGFR, the
kidneys' ability to filter and excrete drugs and their metabolites is significantly impaired.
This leads to drug accumulation and increased risk of toxicity. While renal impairment
can secondarily affect some drug distributions (e.g., protein binding changes due to
uremia), the primary pharmacokinetic concern is reduced excretion. Absorption and
hepatic metabolism are less directly affected by renal impairment.
, 4. A patient asks the APRN why some medications are given intravenously rather than
orally. The APRN explains that the intravenous route bypasses which pharmacokinetic
process that significantly reduces bioavailability for many oral drugs?
A. Distribution
B. Protein binding
C. First-pass effect
D. Renal clearance
Correct Answer: C
Rationale: The first-pass effect (first-pass metabolism) occurs when a drug absorbed
from the gastrointestinal tract travels via the portal vein to the liver before entering
systemic circulation. In the liver, CYP450 enzymes metabolize a significant portion of
the drug, reducing its bioavailability. Intravenous administration delivers drugs directly
into systemic circulation, completely bypassing the first-pass effect and achieving 100%
bioavailability (by definition). Distribution, protein binding, and renal clearance occur
after the drug enters circulation regardless of route.
5. A 55-year-old patient is started on warfarin 5 mg daily. The APRN explains that it will
take approximately 5–7 days to achieve a therapeutic INR. Which pharmacokinetic
concept best explains this delayed therapeutic effect?
A. Zero-order kinetics
B. Steady-state concentration
C. Loading dose requirement
